<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499733</url>
  </required_header>
  <id_info>
    <org_study_id>J0685</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>NA_00003073</secondary_id>
    <secondary_id>JHOC-J0685</secondary_id>
    <secondary_id>CDR0000554417</secondary_id>
    <nct_id>NCT00499733</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer</brief_title>
  <official_title>Sequential Administration of Cryoablation and Cyclophosphamide for Advanced Solid Epithelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to&#xD;
      stop the growth of cancer cells, either by killing the cells or by stopping them from&#xD;
      dividing. Cryoablation kills cancer cells by freezing them. Giving chemotherapy together with&#xD;
      cryoablation may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving cyclophosphamide together with&#xD;
      cryoablation works in treating patients with advanced or metastatic epithelial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Document radiologic and/or tumor marker response to cryotherapy of tumor lesions&#xD;
           followed by cyclophosphamide.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients undergo percutaneous biopsy of the targeted lesion prior to cryoablation. Patients&#xD;
      then undergo percutaneous or open cryotherapy of the largest or most accessible lesion on day&#xD;
      0. On day 3, patients receive cyclophosphamide IV over 1 hour.&#xD;
&#xD;
      Tumor markers (if applicable) are assessed at baseline and monthly during study until marker&#xD;
      progression.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated per PI decision.&#xD;
  </why_stopped>
  <start_date type="Actual">June 2007</start_date>
  <completion_date type="Actual">January 9, 2013</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, in terms of absences of severe adverse events (SAE) and unacceptable toxicity</measure>
    <time_frame>Two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response, according to RECIST criteria</measure>
    <time_frame>Two years</time_frame>
    <description>tumor response will be measured according to RECIST (Response Evaluation Criteria In Solid Tumors) criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will receive one time intravenous infusion of cyclophosphamide three days after scheduled cryoablation surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>500 mg/m^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <description>Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of epithelial solid tumors of any of the following sites or types:&#xD;
&#xD;
               -  Lung (closed to accrual as of 4/2/2009)&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
               -  Prostate&#xD;
&#xD;
               -  Breast (closed to accrual as of 4/2/2009)&#xD;
&#xD;
               -  Sarcoma (closed to accrual as of 4/2/2009)&#xD;
&#xD;
               -  Colon (closed to accrual as of 4/2/2009)&#xD;
&#xD;
               -  Liver(closed to accrual as of 4/2/2009)&#xD;
&#xD;
               -  Pancreatic (closed to accrual as of 4/2/2009)&#xD;
&#xD;
               -  Bone (closed to accrual as of 4/2/2009)&#xD;
&#xD;
               -  Head and neck (closed to accrual as of 4/2/2009)&#xD;
&#xD;
               -  Melanoma (closed to accrual as of 4/2/2009)&#xD;
&#xD;
               -  Carcinoma of unknown primary (closed to accrual as of 4/2/2009)&#xD;
&#xD;
          -  Advanced or metastatic disease&#xD;
&#xD;
          -  Ineligible for or unwilling to undergo surgical resection&#xD;
&#xD;
          -  Eligible for cryotherapy but not expected to be cured by cryotherapy alone&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Creatinine &lt; 2.5 mg/dL&#xD;
&#xD;
          -  Platelet count &gt;75,000/mmÂ³&#xD;
&#xD;
          -  INR&lt; 1.5&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No active, uncontrolled infection&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Women of childbearing potential must practice adequate contraception&#xD;
&#xD;
          -  No debilitating medical or psychiatric illness that would preclude giving informed&#xD;
             consent or receiving optimal treatment and follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Rodriguez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brady Urological Institute at Johns Hopkins Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brady Urological Institute at Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <last_update_submitted>January 16, 2019</last_update_submitted>
  <last_update_submitted_qc>January 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carcinoma of unknown primary</keyword>
  <keyword>recurrent carcinoma of unknown primary</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>chondrosarcoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>stage IIIB uterine sarcoma</keyword>
  <keyword>stage IIIC uterine sarcoma</keyword>
  <keyword>stage IIIA uterine sarcoma</keyword>
  <keyword>stage IVA uterine sarcoma</keyword>
  <keyword>stage IVB uterine sarcoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>recurrent childhood liver cancer</keyword>
  <keyword>stage III childhood liver cancer</keyword>
  <keyword>stage IV childhood liver cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>localized osteosarcoma</keyword>
  <keyword>malignant giant cell tumor of bone</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage III basal cell carcinoma of the lip</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>high-grade salivary gland mucoepidermoid carcinoma</keyword>
  <keyword>salivary gland adenocarcinoma</keyword>
  <keyword>salivary gland adenoid cystic carcinoma</keyword>
  <keyword>salivary gland anaplastic carcinoma</keyword>
  <keyword>salivary gland malignant mixed cell type tumor</keyword>
  <keyword>salivary gland poorly differentiated carcinoma</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>low-grade salivary gland mucoepidermoid carcinoma</keyword>
  <keyword>salivary gland acinic cell tumor</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>newly diagnosed carcinoma of unknown primary</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>conjunctival melanoma</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <keyword>stage IIIA melanoma</keyword>
  <keyword>stage IIIB melanoma</keyword>
  <keyword>stage IIIC melanoma</keyword>
  <keyword>tongue cancer</keyword>
  <keyword>stage IIIA intraocular melanoma</keyword>
  <keyword>stage IIIB intraocular melanoma</keyword>
  <keyword>stage IIIC intraocular melanoma</keyword>
  <keyword>stage IV intraocular melanoma</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

